Helicobacter Pylori Testing Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Description

The Global Helicobacter Pylori (H. Pylori) Testing Market was valued at USD 483 million in 2023, with a projected growth rate of 6.8% over the forecast period. This growth is driven by the increasing prevalence of gastrointestinal disorders, a rising demand for point-of-care (PoC) testing, and the growing adoption of non-invasive H. pylori tests.

A major factor contributing to the market's expansion is the rise in gastric ulcer cases, often caused by H. pylori infections. Factors such as stress, smoking, and the overuse of nonsteroidal anti-inflammatory drugs (NSAIDs) contribute to the increased incidence of gastric ulcers, fueling the demand for diagnostic testing. According to the American Gastroenterological Association (AGA), H. pylori is present in 70-90% of patients with peptic ulcers, highlighting the critical role of testing in managing ulcer-related conditions.

H. pylori testing encompasses various diagnostic procedures to detect the presence of the bacterium in the gastrointestinal tract. This bacterium is associated with conditions such as peptic ulcers, chronic gastritis, and, in some cases, gastric cancer. Accurate testing aids in diagnosing infections, guiding treatment, and monitoring therapy effectiveness.

The market is segmented by test type into invasive and non-invasive tests, with the non-invasive segment holding a dominant 56.6% market share in 2023. Non-invasive tests like the urea breath test (UBT) and stool antigen test (SAT) are preferred for their minimal discomfort, rapid results, and suitability for all age groups. These advantages make non-invasive tests a popular choice among healthcare providers, contributing to segment growth.

The market is further categorized by method into PoC and laboratory-based tests, with the latter accounting for the largest market share, valued at USD 300.6 million in 2023. Laboratory-based tests, such as polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA), offer high sensitivity and specificity, playing a crucial role in accurately diagnosing H. pylori infections and monitoring antibiotic resistance.

In terms of end use , diagnostic laboratories dominated the market in 2023 and are expected to reach USD 390.9 million by 2032. These laboratories offer specialized testing services, aiding in timely diagnoses and effective treatment planning.

The North American H. pylori testing market was valued at USD 170.1 million in 2023, with a projected CAGR of 4.3%. The region's market growth is driven by the rising prevalence of gastric cancers and growing awareness of H. pylori infections, supported by ongoing innovations in diagnostic technologies.

Product Code: 4408

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rise in prevalence of gastric ulcer
  - 3.2.1.2 Increasing geriatric population at risk
  - 3.2.1.3 Growing demand for point-of-care testing devices
  - 3.2.1.4 Rising adoption of non-invasive H. pylori testing
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Lack of skilled professionals for invasive testing
  - 3.2.2.2 Lack of awareness regarding H. pylori infection
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Regulatory landscape
3.6 Technology landscape
3.7 Pricing analysis
3.8 Porter's analysis
3.9 PESTEL analysis
3.10 Gap analysis
3.11 Future market trends

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Invasive
- 5.2.1 Histology
- 5.2.2 Rapid urease test
- 5.2.3 HP culture
5.3 Non-invasive
- 5.3.1 Serologic test
- 5.3.2 Urea breath test
- 5.3.3 Stool/fecal antigen test

Chapter 6 Market Estimates and Forecast, By Method, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Point of care (POC) tests
6.3 Laboratory based tests

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Clinics
7.4 Diagnostic laboratories
7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

9.1 Abbott Laboratories
9.2 Advance Pharma
9.3 Avanos Corporate
9.4 Biohit Oyj
9.5 bioMerieux SA
9.6 Bio-Rad Laboratories, Inc.
9.7 Cardinal Health, Inc.
9.8 Epitope Diagnostics
9.9 Gulf Coast Scientific
9.10 Laboratory Corporation of America, Inc.
9.11 Medline Industries
9.12 Meridian Biosciences, Inc.
9.13 Quidel Corporation
9.14 TECHLAB, Inc
9.15 Thermo Fischer Scientific Corporation